DrugPatentWatch Database Preview
CLINICAL TRIALS PROFILE FOR ZOLOFT
Clinical Trials for Zoloft
| Trial ID | Title | Status | Sponsor | Phase | Summary |
|---|---|---|---|---|---|
| NCT00000440 | Sertraline and Naltrexone for Alcohol Dependence | Completed | National Institute on Alcohol Abuse and Alcoholism (NIAAA) | Phase 2 | This study is a double-blind, placebo-controlled outpatient trial to improve, through the addition of sertraline (Zoloft), the abstinence and relapse rates in alcohol- dependent individuals currently taking naltrexone (Revia). |
| NCT00000446 | Drug Treatment for Alcoholics With Post-Traumatic Stress Disorder | Completed | National Institute on Alcohol Abuse and Alcoholism (NIAAA) | Phase 2 | This study will investigate the use of sertraline (Zoloft) to decrease alcohol consumption and crime-related post-traumatic stress disorder in those individuals with both disorders. This will be a 12-week, placebo-controlled, double-blind outpatient trial. All subjects will receive cognitive behavioral therapy in addition to a placebo or sertraline. Comprehensive evaluation will be done at study entry; treatment termination; and 6, 9, and 12 months after study entry. |
| NCT00000451 | Drug Therapy for Alcohol Dependence in Alaska Natives (Naltrexone/Sertraline) | Completed | National Institute on Alcohol Abuse and Alcoholism (NIAAA) | Phase 2 | This study will assess the ability of naltrexone (Revia) to reduce the risk of relapse in Alaska natives with alcohol dependence. The study will also examine whether a combination of naltrexone and sertraline (Zoloft) yields better abstinence rates than naltrexone used alone. Alaska Native individuals will be recruited into a 16 week outpatient study. |
| NCT00000451 | Drug Therapy for Alcohol Dependence in Alaska Natives (Naltrexone/Sertraline) | Completed | Yale University | Phase 2 | This study will assess the ability of naltrexone (Revia) to reduce the risk of relapse in Alaska natives with alcohol dependence. The study will also examine whether a combination of naltrexone and sertraline (Zoloft) yields better abstinence rates than naltrexone used alone. Alaska Native individuals will be recruited into a 16 week outpatient study. |
| NCT00000458 | Sertraline and Cognitive Therapy in Depressed Alcoholics | Completed | National Institute on Alcohol Abuse and Alcoholism (NIAAA) | Phase 2 | This study will assess whether individuals treated with sertraline (Zoloft) and cognitive behavior therapy will experience improvement with their depression and consume less alcohol than individuals treated with a placebo and cognitive behavior therapy. This is a 12-week, random assignment, placebo-controlled, double-blind study with followup assessments 1 and 3 months after treatment. |
| Trial ID | Title | Status | Sponsor | Phase | Summary |
Clinical Trial Conditions for Zoloft
Condition Name
Condition MeSH
Clinical Trial Locations for Zoloft
Trials by Country
Clinical Trial Progress for Zoloft
Clinical Trial Phase
Clinical Trial Sponsors for Zoloft
Sponsor Name
